Meeting
2022 ASCO Annual Meeting
Use of Merlin Assay to identify patients with a low-risk for SN metastasis in a prospective multicenter Dutch study of a primary melanoma gene-signature (CP-GEP model) to predict sentinel node status during COVID-19.
Authors
Robert Stassen
Erasmus MC Kankerinstituut, Rotterdam, Netherlands
Robert Stassen , Evalyn Mulder , Antoine Veringa , Antien Mooyaart , Jvalini Dwarkasing , Dennie Tempel , Jos A. van der Hage , Sandra Lendfers , Maureen J.B. Aarts , Cornelis Verhoef , Anne Brecht Francken , Dirk J. Grunhagen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9571)
DOI
10.1200/JCO.2022.40.16_suppl.9571
Abstract #
9571
Poster Bd #
164
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Gene expression profile test (GEP) prediction of metastasis-free (MFS) and overall survival (OS) in a cohort of cutaneous melanoma (CM) patients undergoing sentinel lymph node biopsy (SLNB).
First Author: David H. Lawson
Poster
2017 ASCO Annual Meeting
Performance of a 31-gene expression profile (GEP) test for metastatic risk prediction in cutaneous melanomas (CM) of the head and neck.
First Author: John T. Vetto
Poster
2023 ASCO Annual Meeting
Population-based validation of the Melanoma Institute Australia (MIA) and the Memorial Sloan-Kettering Cancer Center (MSKCC) predictive tool for sentinel node status in patients with melanoma.
First Author: Rasmus Mikiver
Poster
2022 ASCO Annual Meeting
MERLIN_001: A prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of patients with SN-negative melanoma.
First Author: Tina J. Hieken